Trem2em1Npa
Endonuclease-mediated Allele Detail
|
|
| Symbol: |
Trem2em1Npa |
| Name: |
triggering receptor expressed on myeloid cells 2; endonuclease-mediated mutation 1, Novartis Pharma AG |
| MGI ID: |
MGI:7507636 |
| Synonyms: |
Trem2-IPD |
| Gene: |
Trem2 Location: Chr17:48653429-48659304 bp, + strand Genetic Position: Chr17, 23.99 cM, cytoband C
|
| Alliance: |
Trem2em1Npa page
|
|
|
|
| Allele Type: |
|
Endonuclease-mediated (Not Applicable) |
| Mutation: |
|
Nucleotide substitutions
|
| |
|
Mutation details: CRISPR/Cas9 technology generated a CACAGCACC to ATCCCCGAC change, resulting in the substitution of amino acids histidine 157, serine 158 and threonine 159 (HST) to isoleucine, proline, and aspartate (IPD). IPD are the least-preferred amino acids for the sub-site biding of ADAM10/17 and this change is expected to reduce TREM2 proteolytic cleavage.
(J:337819)
|
|
|
| Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
| Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
| Carrying any Trem2 Mutation: |
69 strains or lines available
|
|
| Original: |
J:337819 Dhandapani R, et al., Sustained Trem2 stabilization accelerates microglia heterogeneity and Abeta pathology in a mouse model of Alzheimer's disease. Cell Rep. 2022 May 31;39(9):110883 |
| All: |
2 reference(s) |
|